Loading...
Market
Integration status of Mariana Oncology into Novartis by May 2024
5
Resolution / Starting Odds
Fully Integrated • 33%
Partially Integrated • 33%
Integration Delayed • 33%
Novartis operational updates or major business news outlets
Story
Novartis Buys Private U.S. Radiopharma Firm Mariana Oncology for $1.75B
May 2, 2024, 11:29 AM
Novartis has announced the acquisition of U.S. private radiopharmaceutical company Mariana Oncology for $1 billion, with an additional up to $750 million contingent on milestones. This strategic move aims to strengthen Novartis' position in the radioligand therapy (RLT) space, enhancing its pipeline of drugs targeting cancer cells specifically. The acquisition, backed by investors including Atlas Venture, Access Biotechnology, and RA Capital Management, is part of Novartis' broader strategy to expand its leadership in the radiopharmaceutical field, where it already produces leading drugs.
View original story
Similar markets
Approved in USA • 25%
Approved in EU • 25%
Approved in both USA and EU • 25%
Not approved in either • 25%
Fully integrated by mid-2025 • 25%
Fully integrated by end of 2025 • 25%
Integration delayed beyond 2025 • 25%
Integration halted or reversed • 25%
Approved in EU • 25%
Approved in Asia • 25%
Approved in LATAM • 25%
Not approved in other regions • 25%
No collaboration • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Becomes a top 5 vaccine company • 25%
Remains outside top 5 but improves position • 25%
No significant change in market position • 25%
Declines in market position • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increase over 200% • 25%
Increase 100-200% • 25%
Increase up to 100% • 25%
Decrease or no change • 25%